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Abstract
OBJECTIVE: To investigate the efficacy and safety
of intravenous cervus and cucumis polypeptides
for treating avascular necrosis of the femoral head
(ANFH) in regard to pain and hip function in a ran-
domized clinical trial.
METHODS: A total of 96 subjects with ANFH who
were recruited at the Orthopaedic Hospital Affiliat-
ed with Hebei United University and Qian Hai Fem-
oral Head Hospital of Beijing were assigned by lot-
tery to an intervention group (n = 48) or a control
group (n = 48). All subjects underwent physical
therapy and rehabilitation exercises. In addition,
subjects in the intervention group were given intra-
venous infusions of cervus and cucumis polypep-
tides. Visual analogue scale (VAS), Harris hip score,
and radiography or magnetic resonance imaging
were applied to assess all subjects at the beginning
of treatment and 3, 6, and 9 months afterward. All
the subjects were followed up for 2 years.
RESULTS: At the beginning of treatment, there
were no statistically significant differences be-
tween the two groups in terms of the general con-
dition of patients or the VAS and Harris hip scores
(all P > 0.05). At 3, 6, and 9 months after treatment,
however, the VAS score decreased and the Harris
hip score increased in all patients, with the im-
provement of intervention group significantly
greater than that of the control group (P < 0.05).
The total effectiveness rates for the intervention
and control groups were 89.58% and 70.83% , re-
spectively, with the difference being statistically sig-
nificant (P < 0.05). There was no statistically signifi-
cant difference between the two groups in terms of
the safety of the injections (P > 0.05).
CONCLUSION: Intravenous infusion of cervus
and cucumis polypeptides relieved pain and im-
proved hip function of subjects with ANFH.
Thus, the intravenous infusion of cervus and cu-
cumis polypeptides was a safe, effective treat-
ment for ANFH.
© 2016 JTCM.
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INTRODUCTION
With advances in modern medical technology, an in-
creasing number of patients with avascular necrosis of
femoral head (ANFH) are being diagnosed.1,2 In the
past, there was no effective treatment for those who de-
veloped ANFH, and they were vulnerable to disability.
Although currently there are more methods for treat-
ing ANFH,3,4 reversing the mechanism of bone necro-
sis has not yet been established. Some experiments
have shown, however, that a variety of Chinese drugs
had a therapeutic effect on ANFH.5-7 The use of cervus
and cucumis polypeptides has been suggested as a non-
invasive treatment of ANFH and has been reported to
obtain a therapeutic effect.
MATERIALS ANDMETHODS
Source of cases
All subjects were attending the Department of Ortho-
pedic of the Orthopaedic Hospital Affiliated with He-
bei United University and Qian Hai Femoral Head
Hospital of Beijing between June 2009 and June 2010.
Criteria for diagnosis
According to plain radiography, computed tomogra-
phy, magnetic resonance imaging (MRI), radionuclide
bone scans and other tests, all subjects had a confirmed
diagnosis of ANFH. The diagnostic criteria of ANFH
were in line with those in the relevant literature.8
Exclusion criteria
Subjects with necrosis of the femoral head caused by
factors such as tuberculosis, infection, or a tumor were
excluded from the study. Also excluded were subjects
who had other co-morbidities, including diabetes, high
blood pressure ( > 140/90 mm Hg), depression, hyper-
thyroidism, pregnancy, severe liver or other organ dys-
function, coagulation abnormalities, implanted cardiac
pacemakers, and acquired immune deficiency virus in-
fection.
Ethical considerations
All subjects signed the consent form to participate in
the study. The Medical Reproductive Ethics Commit-
tee of the Orthopaedic Hospital Affiliated with Hebei
United University approved this research.
Randomized pattern and clinical information
A total of 96 subjects were randomly allocated, by lot-
tery, to an intervention group or a control group, with
a 1∶1 allocation ratio. All subjects were recruited at the
Department of Orthopedic of the Orthopaedic Hospi-
tal Affiliated with Hebei United University and Qian
Hai Femoral Head Hospital of Beijing. There were 65
men and 31 women, with an average age of (41.8 ±
14.0) years (range 18-72 years). Duration of ANFH
ranged from 2 months to 12 years [average (2.8 ± 3.2)
years]. There were 32 unilateral cases and 64 bilateral
cases. The causes of ANFH included alcoholism in 28
cases, steroid use in 30 cases, trauma in 15 cases, and
other causes in 23 cases. No one in either group
dropped out or was excluded. Association Research Cir-
culation Osseous (ARCO) staging criteria were used.9
There were no statistically significant differences in
terms of age, sex, disease duration, ARCO stage,
causes, location (left or right, single or double), or oth-
er differences between the groups (all P > 0.05).
Blinding
An independent researcher who was not informed of
the treatment sequence or the patient had received
treatment prior to each outcome measurement assessed.
Intervention method
The subjects in the intervention group were given 24 mg
cervus and cucumis polypeptide (Harbin Gloria Phar-
maceuticals Co., Ltd., Heilongjiang, China) dissolved
in 250 mL 5% dextrose injection (or 0.9% sodium
chloride) via intravenous infusion once a day for 15
days as the course of treatment. The intervention
group also underwent the same regimen as the control
group, which consisted of extracorporeal shock wave
therapy and rehabilitation exercises. The orthopedic ex-
tracorporeal shock wave treatment (Shenzhen Huikang
Medical Apparatus Co., Ltd., Shenzhen, China) con-
sisted of 1000-2000 shocks for one therapeutic dose,
once daily, for 14 days. Functional rehabilitation exer-
cises included squatting, opening and closing of lower
limbs, limb shaking and rotation, hip joint flexion and
extension, and riding a bicycle. The action range was
gradually increased, as was the action time. Rehabilita-
tion exercises were applied that could be used long
term once or twice a day and under periodic profession-
al guidance.
Variables assessed
All subjects were evaluated by the Harris hip score,
which including assessments of pain, function, defor-
mity, and motion, as described in the literature.10 The
degree of hip pain was also evaluated by a visual ana-
logue scale (VAS) score (quantifying the number of
points on the VAS scale: e.g., a 5-point VAS scale). The
VAS and Harris scores were recorded respectively, and
plain radiography or MRI was undertaken at the begin-
ning of treatment and 3, 6, and 9 months afterward.
Efficacy evaluation
The standard of the effect of treatment was that de-
scribed in the relevant literature.3 It included its effec-
tiveness for alleviating pain and improving joint func-
tion ¾ whether these two parameters had achieved nor-
mal levels or how close they were to full recovery. Radi-
ography showed that the bone density was even, cystic
necrosis was reduced or at least no worse, trabecular
bone had been reproduced, and joint space was nor-
mal. Marked effects included clinical symptom relief,
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improved joint function, and that the cystic necrosis
was under control. Ineffectiveness of the treatment in-
cluded no significant alleviation of clinical symptoms,
no improvement of joint function, and cystic necrosis
that appeared aggravated or that resulted in femoral
collapse.
Safety evaluation
The safety of the treatment was evaluated in all sub-
jects in the two groups. Adverse events (e.g., nausea,
dizziness, diarrhea, palpitation) were recorded before
and after treatment for all subjects Any changes in
blood pressure, pulse, blood, urine, electrocardiogram,
and other indicators were recorded for all subjects be-
fore and after treatment.
Statistical analysis
Statistical software SPSS 17.0 (SPSS Inc., Chicago, IL,
USA) was used to analyze data. Measurement data are
presented as mean ± standard deviation ( xˉ ± s). Stu-
dent's t-test was applied to the two groups, and the F
test of variance was used for multiple groups. The χ2
test was used to analyze numeration data. The
Mann-Whitney test was used for nonparametric vari-
ables. P < 0.05 was regarded as denoting statistical sig-
nificance.
RESULTS
Baseline characteristics
The subjects were divided into the intervention group
(48 cases) and the control group (48 cases) by lottery.
None of the subjects of the subjects in either group
dropped out or were excluded. The study design is de-
picted in Figure 1.
There was no statistically significant difference (P >
0.05) between the two groups in terms of age, sex,
disease duration, ARCO stage, causes, location (left
or right, single or double), or other parameters (Ta-
ble 1).
Item
Gender (male / female, cases)
Age (years)
Location (single /double, cases)
Duration (years)
Stage (Ⅰ/ Ⅱ / Ⅲ / Ⅳ, hips)
Causes (alcohol / hormone / trauma / others)
Intervention group (n = 48)
35/13
41±14
17/31
3±3
11/24/28/16
13/16/7/12
Control group (n = 48)
30/18
43±15
15/33
3±3
12/27/25/17
15/14/8/11
χ2/t/Z value
1.191
0.520
0.188
0.259
0.287
0.386
P value
0.275
0.604
0.665
0.795
0.774
0.943
Notes: the intervention group received 24 mg cervus and cucumis polypeptide dissolved in 250 mL 5% dextrose injection (or 0.9% sodi-
um chloride injection) via intravenous infusion, once a day, for 15 days. They also underwent the same treatment as the control group: ex-
tracorporeal shock wave therapy (1000-2000 times/dose, once daily, for 14 days) and rehabilitation exercises.
Table 1 Comparison of baseline characteristics of the intervention and control groups ( xˉ ± s)
Assessed for eligibility
(n = 96)
Excluded (n = 0)
Notmeeting inclusion criteria
(n=0)
Declined to participate (n = 0)
Randomized (n = 96)
Allocated to intervention (n = 48).
Underwent cervus and cucumis poly-
peptide injection, physical therapy, and
rehabilitation exercises
Allocated to control (n = 48).
Underwent physical therapy and
rehabilitation exercises
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Analyzed (n = 48) Analyzed (n = 48)
Figure 1 Flow diagram for this study
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VAS score
At the beginning of treatment (0 month), there was no
statistically significant difference between the two
groups in terms of the VAS scores (t0 = 0.278, P >
0.05). At 3, 6, and 9 months after treatment, the VAS
scores in the two groups decreased, and the differences
were statistically significant (t3 = 5.696, t6 = 4.980, t9 =
8.458, P < 0.05) (Figure 2).
Harris hip score
At the beginning of treatment (0 months), there was
no statistically significant difference between the two
groups in terms of the Harris hip scores (t0 = 1.369,
P > 0.05). At 3, 6, and 9 months after treatment, the
Harris hip scores in both of the two groups increased,
and the differences were statistically significant (t3 =
7.747, t6 = 3.457, t9 = 4.569, P < 0.05) (Figure 3).
Efficacy and safety
The total effectiveness rates (effective and markedly ef-
fective) for the intervention and control groups were
89.58% and 70.83%, respectively. The Mann-Whitney
U-test was used to compare the efficacy of the two
groups, and the difference was statistically significant
(Z = −2.403, P < 0.05). There were no statistically sig-
nificant differences between the two groups in terms of
changes in vital signs or laboratory results. Three sub-
jects developed adverse reactions, including two
(4.17%) in the intervention group (mild nausea due to
the medication) and one (2.08%) in the control group
(mild dizziness), whose symptom disappeared without
treatment. Fisher's test was used to assess the safety in
the two groups, and the difference was not statistically
significant (P > 0.05) (Table 2).
Comparison of radiography results in the
intervention group before and after treatment
Deformation or collapse of the femoral head (FH) was
not observed in either group. Before and 9 months af-
ter treatment, radiography of the hips in the interven-
tion group showed no deformation or collapse of the
FH (Figure 4).
DISCUSSION
ANFH is one of the most difficult orthopedic disor-
ders to treat. In Traditional Chinese Medicine, it is
called "bone loss." The etiology and pathogenesis of
ANFH are not yet fully understood, and multiple fac-
tors may give rise to ANFH.11 Once avascular necrosis
is established and treatment is not timely, the FH be-
comes deformed, sometimes even collapsing, causing
hip dysfunction. Patients may lose their ability to
work, creating great burdens for the family and society.12
Figure 2 Comparison of VAS scores: intervention group com-
pared with control group
The intervention group received 24 mg cervus and cucumis
polypeptide dissolved in 250 mL 5% dextrose injection (or
0.9% sodium chloride injection) via intravenous infusion,
once a day, for 15 days. They also underwent the same treat-
ment as the control group: extracorporeal shock wave thera-
py (1000-2000 times/dose, once daily, for 14 days) and reha-
bilitation exercises. Compared with control group, aP < 0.05.
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Figure 3 Comparison of Harris hip scores: intervention group
compared with control group
The intervention group received 24 mg cervus and cucumis
polypeptide dissolved in 250 mL 5% dextrose injection (or
0.9% sodium chloride injection) via intravenous infusion,
once a day, for 15 days. They also underwent the same
treatment as the control group: extracorporeal shock wave
therapy (1000-2000 times/dose, once daily, for 14 days) and
rehabilitation exercises. Compared with control group, aP <
0.05.
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Figure 4 Comparison of plain radiographs in the interven-
tion group before and after treatment
A, B: At the beginning of treatment, the radiographs show
low-density areas and dense shadows in the bilateral femo-
ral head. C, D: nine months after treatment, the radiographs
show that the density of the original low-density area has in-
creased. Femoral head cartilage collapse did not occur, joint
space did not narrow, and the articular cartilage surface is
now smooth.
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There are various perspectives about treating ANFH.13
Vascular regeneration and new bone formation are es-
sential to reverse the pathological process during treat-
ment. Several noninvasive treatments have been recom-
mended for use at an early stage of ANFH, with most
studies having reported satisfactory outcomes.14-16 Total
hip arthroplasty (THA) is usually recommended for
late-stage cases.17 For young, active patients, however,
there are many complications with THA, including
thigh pain, polyethylene wear, osteolysis, and compo-
nent loosening.18 Therefore, treatment of THA in the
young remains controversial.
The derivation of cervus and cucumis polypeptides is
sika deer bones and dried, ripe seeds of melons. The
main components include osteoinductive polypeptide
biological factors, sweet pumpkin seed extract, a vari-
ety of free amino acids, organic calcium, and other in-
gredients. Osteoinductive polypeptide biological fac-
tors include bone morphogenetic proteins, β-trans-
forming growth factor, and fibroblast growth factor,
which effectively promote the formation and resorp-
tion of bone, have a variety of biological activities, and
promote bone regeneration and bone metabolism. Ex-
tracts from sweet pumpkin seeds can reduce inflamma-
tory exudation, promote recovery of the local blood
supply, and inhibit the release of prostaglandins, there-
by achieving an analgesic effect. Organic calcium and
phosphate ions may participate in the metabolism of
calcium and phosphorus, which can maintain bone vol-
ume and so provide raw materials for repairing necrot-
ic areas of the femoral head.
In this study, patients in the intervention group were
given intravenous infusions of cervus and cucumis
polypeptides. At 3, 6, and 9 months after treatment,
there were statistically significant differences between
the two groups in terms of the Harris hip and VAS
scores (P < 0.05). The total effectiveness rate in the in-
tervention group was 89.58%, confirming that intrave-
nous cervus and cucumis polypeptides have a positive
effect on ANFH, consistent with the findings of other
studies.19
We also demonstrated that the safety of this treatment
in the intervention group was same as that of the con-
trol group. Only two intervention patients had a mild
adverse reaction. Thus, the treatment was tolerated.
None of the subjects in either group had to terminate
the study because of adverse reactions.
The use of intravenous cervus and cucumis polypep-
tides is classified as slow-acting in Traditional Chinese
Medicine. Its unique mechanism of action, good clini-
cal efficacy, and safety are gradually proving to have a
clear advantage for treating ANFH and that it is wor-
thy of clinical application. In the present study, howev-
er, we can speak only for the short-term effects of intra-
venous cervus and cucumis polypeptides versus physi-
cal therapy and rehabilitation alone. The results are
based only on the patients' hip function, symptoms,
and short-term adverse reactions. To date, the
long-term hip bone structural improvements and the
protective effect could not be assessed. Thus,
long-term clinical trials are needed to evaluate the
long-term effects of intravenous cervus and cucumis
polypeptides for treating ANFH.
In summary, intravenous cervus and cucumis polypep-
tides were significantly effective for relieving pain and
improving hip function. Thus, we suggest that intrave-
nous cervus and cucumis polypeptides are safe and ef-
fective for treating ANFH and are worthy of clinical
application and promotion.
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